Abstract
Biologic agents, especially TNFα inhibitors, appear to be very effective in treatment of rheumatoid arthritis (RA). Although the use of biologic agents has greatly improved the therapeutic efficacy in management of RA, biologic therapies for RA treatment have several limitations. These agents fail to achieve complete remission in substantial portion of RA patients. Also certain adverse events have been observed, including serious bacterial infections and reactivation of latent tuberculosis. Previous reports demonstrated that TNFα inhibitors are more efficacious in combination with other drugs such as methotrexate. In this report, we suggest that paricalcitol, a synthetic vitamin D analog is another candidate molecule for combination therapy with TNFα inhibitors in RA.
| Original language | English |
|---|---|
| Pages (from-to) | 634-635 |
| Number of pages | 2 |
| Journal | Medical Hypotheses |
| Volume | 75 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2010 Dec 1 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Paricalcitol, a synthetic vitamin D analog : A candidate for combination therapy with biological agents in rheumatoid arthritis. / Kim, Tae Hwan; Ji, Jong Dae.
In: Medical Hypotheses, Vol. 75, No. 6, 01.12.2010, p. 634-635.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Paricalcitol, a synthetic vitamin D analog
T2 - A candidate for combination therapy with biological agents in rheumatoid arthritis
AU - Kim, Tae Hwan
AU - Ji, Jong Dae
PY - 2010/12/1
Y1 - 2010/12/1
N2 - Biologic agents, especially TNFα inhibitors, appear to be very effective in treatment of rheumatoid arthritis (RA). Although the use of biologic agents has greatly improved the therapeutic efficacy in management of RA, biologic therapies for RA treatment have several limitations. These agents fail to achieve complete remission in substantial portion of RA patients. Also certain adverse events have been observed, including serious bacterial infections and reactivation of latent tuberculosis. Previous reports demonstrated that TNFα inhibitors are more efficacious in combination with other drugs such as methotrexate. In this report, we suggest that paricalcitol, a synthetic vitamin D analog is another candidate molecule for combination therapy with TNFα inhibitors in RA.
AB - Biologic agents, especially TNFα inhibitors, appear to be very effective in treatment of rheumatoid arthritis (RA). Although the use of biologic agents has greatly improved the therapeutic efficacy in management of RA, biologic therapies for RA treatment have several limitations. These agents fail to achieve complete remission in substantial portion of RA patients. Also certain adverse events have been observed, including serious bacterial infections and reactivation of latent tuberculosis. Previous reports demonstrated that TNFα inhibitors are more efficacious in combination with other drugs such as methotrexate. In this report, we suggest that paricalcitol, a synthetic vitamin D analog is another candidate molecule for combination therapy with TNFα inhibitors in RA.
UR - http://www.scopus.com/inward/record.url?scp=77958457182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958457182&partnerID=8YFLogxK
U2 - 10.1016/j.mehy.2010.08.003
DO - 10.1016/j.mehy.2010.08.003
M3 - Article
C2 - 20736134
AN - SCOPUS:77958457182
VL - 75
SP - 634
EP - 635
JO - Medical Hypotheses
JF - Medical Hypotheses
SN - 0306-9877
IS - 6
ER -